Betül Kuz, Mustafa Ertuğrul Yaşa, Rıza Sonkaya, Selman Aktaş
Introduction
Lower urinary tract symptoms (LUTS) in Parkinson's disease (PD) primarily result from neurological abnormalities. Yet, the impact of postural abnormalities and muscular rigidity on lower urinary tract symptoms remains unclear. This study aims to compare spinal alignment and trunk mobility in PD patients with and without LUTS.
Methods
A total of 93 patients were included in this cross-sectional study. Two groups were created based on the presence of LUTS. The study was completed with 57 symptomatic and 36 asymptomatic patients. The presence of LUTS was determined using the International Prostate Symptom Score. The Urinary Symptom Profile questionnaire was used for LUTS classification. Spinal posture and trunk mobility were measured using the Spinal Mouse.
Results
Compared to the asymptomatic controls, decreased lumbar lordosis (p = 0.022) and increased anterior trunk tilt (p = 0.026) were evident in symptomatic patients. However, no significant differences were found in thoracic kyphosis or lateral spinal curvatures (p > 0.05). Asymptomatic patients demonstrated greater lumbar mobility and total trunk mobility in both the sagittal plane (p = 0.002; p = 0.023) and the frontal plane (p = 0.024; p = 0.046), respectively.
Conclusions
PD patients with LUTS demonstrate distinct alterations in spinal alignment and trunk mobility compared to those without symptoms. These biomechanical differences may reflect compensatory mechanisms or additional motor involvement contributing to urinary dysfunction in this population.
帕金森病（PD）的下尿路症状（LUTS）主要由神经系统异常引起。然而，姿势异常和肌肉僵硬对下尿路症状的影响尚不清楚。本研究旨在比较伴有和不伴有LUTS的PD患者的脊柱对齐和躯干活动度。方法对93例患者进行横断面研究。根据LUTS的存在创建了两组。57例有症状患者和36例无症状患者完成了研究。使用国际前列腺症状评分来确定LUTS的存在。泌尿症状问卷用于LUTS分类。使用脊髓鼠测量脊柱姿势和躯干活动度。结果与无症状对照组相比，有症状组腰椎前凸明显减小（p = 0.022），前干倾斜明显增加（p = 0.026）。然而，在胸椎后凸或脊柱侧弯方面没有发现显著差异（p > 0.05）。无症状患者在矢状面（p = 0.002; p = 0.023）和额位面（p = 0.024; p = 0.046）均表现出较大的腰椎活动度和躯干总活动度。结论：与无症状的PD患者相比，伴有LUTS的PD患者在脊柱对齐和躯干活动方面表现出明显的改变。这些生物力学差异可能反映了代偿机制或额外的运动参与导致了该人群的尿功能障碍。
{"title":"A Comparison of Spinal Alignment and Trunk Mobility in Parkinson's Disease Patients With and Without Lower Urinary Tract Symptoms","authors":"Betül Kuz, Mustafa Ertuğrul Yaşa, Rıza Sonkaya, Selman Aktaş","doi":"10.1111/luts.70028","DOIUrl":"https://doi.org/10.1111/luts.70028","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Lower urinary tract symptoms (LUTS) in Parkinson's disease (PD) primarily result from neurological abnormalities. Yet, the impact of postural abnormalities and muscular rigidity on lower urinary tract symptoms remains unclear. This study aims to compare spinal alignment and trunk mobility in PD patients with and without LUTS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 93 patients were included in this cross-sectional study. Two groups were created based on the presence of LUTS. The study was completed with 57 symptomatic and 36 asymptomatic patients. The presence of LUTS was determined using the International Prostate Symptom Score. The Urinary Symptom Profile questionnaire was used for LUTS classification. Spinal posture and trunk mobility were measured using the Spinal Mouse.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared to the asymptomatic controls, decreased lumbar lordosis (<i>p</i> = 0.022) and increased anterior trunk tilt (<i>p</i> = 0.026) were evident in symptomatic patients. However, no significant differences were found in thoracic kyphosis or lateral spinal curvatures (<i>p</i> > 0.05). Asymptomatic patients demonstrated greater lumbar mobility and total trunk mobility in both the sagittal plane (<i>p</i> = 0.002; <i>p</i> = 0.023) and the frontal plane (<i>p</i> = 0.024; <i>p</i> = 0.046), respectively.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>PD patients with LUTS demonstrate distinct alterations in spinal alignment and trunk mobility compared to those without symptoms. These biomechanical differences may reflect compensatory mechanisms or additional motor involvement contributing to urinary dysfunction in this population.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144929819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qinglong Yang, Haolin Chen, Hanyuan Lin, Haoxian Tang, Nan Luo, Xuan Zhang, Jingtao Huang, Xuxia Sui, Qingtao Yang
Objectives
This study aims to examine the association of systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) with the prevalence of overactive bladder (OAB).
Methods
This cross-sectional study analyzed data from 22,343 participants (≥ 20 years) in the National Health and Nutrition Examination Survey (2005–2018). We applied weighted multivariate logistic regression, restricted cubic spline (RCS) regression, subgroup, and sensitivity analyses to assess the associations between SII, NLR, and OAB.
Results
RCS analysis revealed U-shaped relationships with inflection points at 6.13 for ln(SII) and 0.65 for ln(NLR). In the fully adjusted model, ln(SII) ≤ 6.13 showed a negative correlation with OAB (OR = 0.83; 95% CI: 0.70–0.99), while ln(SII) > 6.13 was positively correlated (OR = 1.32; 95% CI: 1.10–1.58). Similarly, ln(NLR) > 0.65 correlated positively with OAB (OR = 1.40; 95% CI: 1.16–1.71). Subgroup analyses revealed significant differences in alcohol use subgroups for ln(SII) ≤ 6.13 and ln(NLR) ≤ 0.65 (P for interaction < 0.05).
Conclusions
SII and NLR may serve as biomarkers for assessing OAB risk.
{"title":"Systemic Immune-Inflammation Index and Neutrophil-To-Lymphocyte Ratio: U-Shaped Association With Overactive Bladder","authors":"Qinglong Yang, Haolin Chen, Hanyuan Lin, Haoxian Tang, Nan Luo, Xuan Zhang, Jingtao Huang, Xuxia Sui, Qingtao Yang","doi":"10.1111/luts.70029","DOIUrl":"https://doi.org/10.1111/luts.70029","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>This study aims to examine the association of systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) with the prevalence of overactive bladder (OAB).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study analyzed data from 22,343 participants (≥ 20 years) in the National Health and Nutrition Examination Survey (2005–2018). We applied weighted multivariate logistic regression, restricted cubic spline (RCS) regression, subgroup, and sensitivity analyses to assess the associations between SII, NLR, and OAB.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>RCS analysis revealed U-shaped relationships with inflection points at 6.13 for ln(SII) and 0.65 for ln(NLR). In the fully adjusted model, ln(SII) ≤ 6.13 showed a negative correlation with OAB (OR = 0.83; 95% CI: 0.70–0.99), while ln(SII) > 6.13 was positively correlated (OR = 1.32; 95% CI: 1.10–1.58). Similarly, ln(NLR) > 0.65 correlated positively with OAB (OR = 1.40; 95% CI: 1.16–1.71). Subgroup analyses revealed significant differences in alcohol use subgroups for ln(SII) ≤ 6.13 and ln(NLR) ≤ 0.65 (<i>P</i> for interaction < 0.05).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>SII and NLR may serve as biomarkers for assessing OAB risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144935336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To explore the particular lower urinary tract symptoms (LUTS) that impact daily life in co-existent overactive and underactive bladder (COUB), overactive bladder (OAB), and underactive bladder (UAB) as symptom syndromes.
Methods
Using data from a nationwide, cross-sectional internet survey of adults aged ≥ 20 conducted in Japan, participants were categorized into COUB, OAB alone, UAB alone, and non-OAB/UAB groups according to the OAB symptom score and the provisional UAB definition of the International Continence Society working group. Participants were asked what symptoms affected their daily lives. The prevalence of LUTS and the particular LUTS affecting daily life were evaluated in each group.
Results
Substantial proportions of participants in all groups had increased daytime frequency and nocturia. Even in the male OAB alone group, the prevalence of voiding symptoms was substantial. In almost all of the groups, storage symptoms accounted for more than approximately 80% of the particular LUTS that had the greatest impact on daily life, and nocturia ranked first, except for the male OAB alone group, with a 32% rate of urgency.
Conclusions
Although multiple LUTS affected daily life in individuals with COUB and UAB, storage symptoms, particularly nocturia, are likely to have the greatest impact of LUTS on daily life in those not only with OAB but also with UAB and COUB.
{"title":"Impact of Lower Urinary Tract Symptoms on Daily Life in Individuals With Co-Existence Overactive and Underactive Bladder, Overactive Bladder, and Underactive Bladder","authors":"Noritoshi Sekido, Kenji Omae, Nobuhiro Haga, Yasue Kubota, Motoaki Saito, Ryuji Sakakibara, Mikako Yoshida, Takahiko Mitsui, Naoya Masumori, Satoru Takahashi","doi":"10.1111/luts.70026","DOIUrl":"https://doi.org/10.1111/luts.70026","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To explore the particular lower urinary tract symptoms (LUTS) that impact daily life in co-existent overactive and underactive bladder (COUB), overactive bladder (OAB), and underactive bladder (UAB) as symptom syndromes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using data from a nationwide, cross-sectional internet survey of adults aged ≥ 20 conducted in Japan, participants were categorized into COUB, OAB alone, UAB alone, and non-OAB/UAB groups according to the OAB symptom score and the provisional UAB definition of the International Continence Society working group. Participants were asked what symptoms affected their daily lives. The prevalence of LUTS and the particular LUTS affecting daily life were evaluated in each group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Substantial proportions of participants in all groups had increased daytime frequency and nocturia. Even in the male OAB alone group, the prevalence of voiding symptoms was substantial. In almost all of the groups, storage symptoms accounted for more than approximately 80% of the particular LUTS that had the greatest impact on daily life, and nocturia ranked first, except for the male OAB alone group, with a 32% rate of urgency.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Although multiple LUTS affected daily life in individuals with COUB and UAB, storage symptoms, particularly nocturia, are likely to have the greatest impact of LUTS on daily life in those not only with OAB but also with UAB and COUB.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/luts.70026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144810939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The present study investigates the therapeutic potential of Cucurbita Pepo L. Seeds' Oil (CPSO) extracted by petroleum ether on testosterone-induced hyperplasia (BPH) in a castrated Wistar rat model.
Materials and Methods
Animals underwent two stages of treatment (28 days each): the testosterone treatment stage, to promote BPH, and the therapeutic stage, which consisted of an oral administration of CPSO. Forty-eight Wistar rats were equally divided into six groups: the negative control; groups 2–6 underwent a bilateral orchidectomy (induced via the scrotal route), then were redistributed into the castrated-control group and the castrated and testosterone-treated groups BPH induction (10 mg/kg). Twenty-eight days after BPH induction, the BPH rats were orally treated with Finasteride (FINA group: 5 mg/kg/d) and CPSO (CPSO-1 group: 40 mg/kg/d; CPSO-2 group: 80 mg/kg/d) for 28 additional days. Plasma biochemical parameters, circulating testosterone (T) and prostate-specific antigen (PSA), prostate oxidative markers, and inflammation were analyzed.
Results
CPSO administration exhibited a decrease in prostate weight, normalized the plasma total proteins, lipids, calcium and glucose, testosterone, and PSA levels, and attenuated the disturbances of liver and kidney functions in BPH rats. At the prostate level, CPSO showed a notably decreased prostate oxidation and inflammation. The histological study showed that CPSO restored prostatic lesions caused by BPH.
Conclusion
According to the present results, we suggest that CPSO could have a protective potential related to its proven anti-oxidant, anti-hyperplastic, and anti-inflammatory properties on preventing testosterone-induced BPH in castrated rats and might be used as an herbal remedy or nutraceutical agent in BPH management.
{"title":"Investigating the Antihyperplastic, Anti-Inflammatory and Antioxidant Properties of Cucurbita Pepo L. Seed Oil on Testosterone- Induced Benign Prostatic Hyperplasia (BPH) in Castrated Rat Model","authors":"Hajji Noura, Khémiri Ikram","doi":"10.1111/luts.70024","DOIUrl":"https://doi.org/10.1111/luts.70024","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The present study investigates the therapeutic potential of <i>Cucurbita Pepo</i> L. Seeds' Oil (CPSO) extracted by petroleum ether on testosterone-induced hyperplasia (BPH) in a castrated Wistar rat model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>Animals underwent two stages of treatment (28 days each): the testosterone treatment stage, to promote BPH, and the therapeutic stage, which consisted of an oral administration of CPSO. Forty-eight Wistar rats were equally divided into six groups: the negative control; groups 2–6 underwent a bilateral orchidectomy (induced via the scrotal route), then were redistributed into the castrated-control group and the castrated and testosterone-treated groups BPH induction (10 mg/kg). Twenty-eight days after BPH induction, the BPH rats were orally treated with Finasteride (FINA group: 5 mg/kg/d) and CPSO (CPSO-1 group: 40 mg/kg/d; CPSO-2 group: 80 mg/kg/d) for 28 additional days. Plasma biochemical parameters, circulating testosterone (T) and prostate-specific antigen (PSA), prostate oxidative markers, and inflammation were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>CPSO administration exhibited a decrease in prostate weight, normalized the plasma total proteins, lipids, calcium and glucose, testosterone, and PSA levels, and attenuated the disturbances of liver and kidney functions in BPH rats. At the prostate level, CPSO showed a notably decreased prostate oxidation and inflammation. The histological study showed that CPSO restored prostatic lesions caused by BPH.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>According to the present results, we suggest that CPSO could have a protective potential related to its proven anti-oxidant, anti-hyperplastic, and anti-inflammatory properties on preventing testosterone-induced BPH in castrated rats and might be used as an herbal remedy or nutraceutical agent in BPH management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eric Woon, Jorge Villalobos Santeli, Jia Liu, Longtu Chen, George Kuchel, Bin Feng
Objective
This study aimed to investigate the potential role of cesium chloride (CsCl), ivabradine (IVA), and isoproterenol (ISO) on the sensory transmission of bladder afferents to graded urinary bladder distension (UBD). We specifically selected these drugs to target the hyperpolarization-activated cyclic nucleotide-gated (HCN) cation channels to determine their role in afferent encoding.
Methods
The bladders of C57BL/6 female mice were harvested with attached pelvic nerves in continuity, and the stimulus–response function (SRF) of bladder afferents to stepped bladder distension (20, 40, 60, 80 cmH2O) was recorded by single-fiber recordings. Their changes in SRF to bath application of CsCl, IVA, and ISO were then evaluated. The presence of HCN on bladder afferent endings was assessed through immunohistological staining on bladder sections from mice with genetically labeled bladder afferents.
Results
IVA and ISO did not significantly reduce afferent responses to UBD, whereas CsCl increased afferent responses. Bladder afferents in the pelvic nerve pathway were categorized into low-firing (LF, < 10 Hz) and high-firing (HF, > 10 Hz) groups. SRF in both the LF and HF groups showed similar trends with no significant changes in response to IVA and ISO. CsCl increased SRF only in the HF group but not in the LF group. Immunohistological staining revealed that HCN1 does not extensively co-localize with afferent endings, showing only sporadic presence.
Conclusion
Our targeted pharmacological studies with single-fiber recordings and immunohistological staining collectively suggest that HCN channels do not play a significant role in bladder afferent sensory transmission.
{"title":"Pharmacological Targeting of Hyperpolarization-Activated Cyclic Nucleotide-Gated Cation Channels on Bladder Afferent Sensory Transmission","authors":"Eric Woon, Jorge Villalobos Santeli, Jia Liu, Longtu Chen, George Kuchel, Bin Feng","doi":"10.1111/luts.70025","DOIUrl":"https://doi.org/10.1111/luts.70025","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to investigate the potential role of cesium chloride (CsCl), ivabradine (IVA), and isoproterenol (ISO) on the sensory transmission of bladder afferents to graded urinary bladder distension (UBD). We specifically selected these drugs to target the hyperpolarization-activated cyclic nucleotide-gated (HCN) cation channels to determine their role in afferent encoding.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The bladders of C57BL/6 female mice were harvested with attached pelvic nerves in continuity, and the stimulus–response function (SRF) of bladder afferents to stepped bladder distension (20, 40, 60, 80 cmH<sub>2</sub>O) was recorded by single-fiber recordings. Their changes in SRF to bath application of CsCl, IVA, and ISO were then evaluated. The presence of HCN on bladder afferent endings was assessed through immunohistological staining on bladder sections from mice with genetically labeled bladder afferents.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>IVA and ISO did not significantly reduce afferent responses to UBD, whereas CsCl increased afferent responses. Bladder afferents in the pelvic nerve pathway were categorized into low-firing (LF, < 10 Hz) and high-firing (HF, > 10 Hz) groups. SRF in both the LF and HF groups showed similar trends with no significant changes in response to IVA and ISO. CsCl increased SRF only in the HF group but not in the LF group. Immunohistological staining revealed that HCN1 does not extensively co-localize with afferent endings, showing only sporadic presence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our targeted pharmacological studies with single-fiber recordings and immunohistological staining collectively suggest that HCN channels do not play a significant role in bladder afferent sensory transmission.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 5","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/luts.70025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Duloxetine has demonstrated efficacy in treating various types of chronic pain conditions. A double-blind clinical trial was conducted to assess the effectiveness and tolerability of duloxetine compared to amitriptyline in women suffering from chronic pelvic pain (CPP) syndrome.
Methods
Sixty-nine eligible women diagnosed with CPP syndrome were randomly assigned to receive either duloxetine or amitriptyline. Duloxetine was initiated at 30 mg/day and amitriptyline at 25 mg/day, with dosages increased to 60 mg/day for duloxetine and 50 mg/day for amitriptyline after the first week and maintained throughout weeks 2 to 8 of the treatment phase. The effectiveness of the treatment was assessed using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and its domain scores at weeks 4 and 8 after treatment. The safety and tolerability of the study medications were assessed using an antidepressant side effect checklist and spontaneous participant reports of adverse effects. All analyses were conducted on an Intention-to-Treat (ITT) analysis data set.
Results
Patients undergoing both medications experienced similar improvements in their total NIH-CPSI scores at weeks 4 and 8. The proportions of patients achieving a response, defined as at least a 6-point reduction in the total NIH-CPSI score at both weeks 4 and 8, were also comparable between the duloxetine and amitriptyline treatments. Further, at the end of the study period, a similar proportion of subjects reported marked or moderate overall symptom improvements with both treatments. However, in the analysis of NIH-CPSI domain scores, duloxetine-treated patients exhibited lower pain domain scores at both study endpoints, while amitriptyline-treated patients achieved better scores in the urinary symptoms domain. Regarding quality of life domain scores, no significant differences were observed between the groups. In terms of safety and tolerability, duloxetine demonstrated more favorable outcomes, with fewer patients experiencing adverse effects and a lower withdrawal rate due to adverse effects compared to amitriptyline.
Conclusions
These findings suggest that duloxetine is as effective as amitriptyline for managing CPP syndrome in women, with the added advantage of a more favorable safety profile.
Trial Registration
The trial was registered at the Iranian Registry of Clinical Trials (identifie
{"title":"Tolerability and Efficacy of Duloxetine Compared to Amitriptyline in Women With Chronic Pelvic Pain Syndrome: Findings From a Clinical Trial","authors":"Maede Mohseni, Rojan Ghaderzadeh, Kimia Bakhtiari, Maryam Zamanirafe, Mona Doostizadeh, Aliasghar Tabatabaeii Mohammadi, Kiumarth Amini, Maryam Mehrpooya","doi":"10.1111/luts.70023","DOIUrl":"https://doi.org/10.1111/luts.70023","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Duloxetine has demonstrated efficacy in treating various types of chronic pain conditions. A double-blind clinical trial was conducted to assess the effectiveness and tolerability of duloxetine compared to amitriptyline in women suffering from chronic pelvic pain (CPP) syndrome.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Sixty-nine eligible women diagnosed with CPP syndrome were randomly assigned to receive either duloxetine or amitriptyline. Duloxetine was initiated at 30 mg/day and amitriptyline at 25 mg/day, with dosages increased to 60 mg/day for duloxetine and 50 mg/day for amitriptyline after the first week and maintained throughout weeks 2 to 8 of the treatment phase. The effectiveness of the treatment was assessed using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) and its domain scores at weeks 4 and 8 after treatment. The safety and tolerability of the study medications were assessed using an antidepressant side effect checklist and spontaneous participant reports of adverse effects. All analyses were conducted on an Intention-to-Treat (ITT) analysis data set.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Patients undergoing both medications experienced similar improvements in their total NIH-CPSI scores at weeks 4 and 8. The proportions of patients achieving a response, defined as at least a 6-point reduction in the total NIH-CPSI score at both weeks 4 and 8, were also comparable between the duloxetine and amitriptyline treatments. Further, at the end of the study period, a similar proportion of subjects reported marked or moderate overall symptom improvements with both treatments. However, in the analysis of NIH-CPSI domain scores, duloxetine-treated patients exhibited lower pain domain scores at both study endpoints, while amitriptyline-treated patients achieved better scores in the urinary symptoms domain. Regarding quality of life domain scores, no significant differences were observed between the groups. In terms of safety and tolerability, duloxetine demonstrated more favorable outcomes, with fewer patients experiencing adverse effects and a lower withdrawal rate due to adverse effects compared to amitriptyline.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings suggest that duloxetine is as effective as amitriptyline for managing CPP syndrome in women, with the added advantage of a more favorable safety profile.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>The trial was registered at the Iranian Registry of Clinical Trials (identifie","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Studies on nurses' and nursing assistants' perceptions of urinary incontinence (UI) in the elderly are well-documented; however, little to no research focuses specifically on physiotherapists. This study aims to explore physiotherapists' perspectives on UI among elderly patients.
Objectives
To assess the knowledge, attitudes, and practices of physiotherapists in France regarding managing UI in elderly patients, and to explore how training influences their confidence and clinical behaviors.
Methods
A cross-sectional online survey was conducted among physiotherapists practicing in France. The questionnaire addressed sociodemographic characteristics, experience with elderly patients with UI, and training in pelvic-perineal rehabilitation. Descriptive statistics and χ2 analyses were used to identify associations.
Results
A total of 106 responses were collected. Among respondents, 80 (75.5%) reported knowing UI in elderly patients, but 62 (58.5%) expressed feeling powerless when managing such cases. Only 62 (58.5%) reported having the skills to help patients with UI, and just 10 (9.4%) used validated assessment tools. Physiotherapists who had received prior training—whether through initial education, continuing education, or self-directed study—were significantly more likely to report confidence, satisfaction, and proper use of tools (p < 0.01). A majority, 75 (70.8%), indicated a need for further training, and 60 (56.6%) expressed the need for clinical guidelines.
Discussion
This study reveals a gap between physiotherapists' knowledge of UI and their ability to manage it confidently in elderly patients. Training was significantly associated with greater competence and use of recommended practices. The underuse of assessment tools and expressed need for clearer guidelines suggest structural gaps in support and education.
Conclusion
Improving UI training and access to standardized tools could enhance physiotherapists' confidence and quality of care. Although conducted in France, these findings may inform international strategies to address similar gaps in geriatric continence care.
{"title":"Knowledge, Attitudes, and Practices of Physiotherapists Regarding the Management of Urinary Incontinence in Elderly Patients in France: A Cross-Sectional Study","authors":"Julie Swiderski, Joëlle Lansonneur Leterme, Fréderic Bloch, François-Régis Sarhan","doi":"10.1111/luts.70022","DOIUrl":"https://doi.org/10.1111/luts.70022","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Context</h3>\u0000 \u0000 <p>Studies on nurses' and nursing assistants' perceptions of urinary incontinence (UI) in the elderly are well-documented; however, little to no research focuses specifically on physiotherapists. This study aims to explore physiotherapists' perspectives on UI among elderly patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To assess the knowledge, attitudes, and practices of physiotherapists in France regarding managing UI in elderly patients, and to explore how training influences their confidence and clinical behaviors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A cross-sectional online survey was conducted among physiotherapists practicing in France. The questionnaire addressed sociodemographic characteristics, experience with elderly patients with UI, and training in pelvic-perineal rehabilitation. Descriptive statistics and <i>χ</i><sup>2</sup> analyses were used to identify associations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 106 responses were collected. Among respondents, 80 (75.5%) reported knowing UI in elderly patients, but 62 (58.5%) expressed feeling powerless when managing such cases. Only 62 (58.5%) reported having the skills to help patients with UI, and just 10 (9.4%) used validated assessment tools. Physiotherapists who had received prior training—whether through initial education, continuing education, or self-directed study—were significantly more likely to report confidence, satisfaction, and proper use of tools (<i>p</i> < 0.01). A majority, 75 (70.8%), indicated a need for further training, and 60 (56.6%) expressed the need for clinical guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>This study reveals a gap between physiotherapists' knowledge of UI and their ability to manage it confidently in elderly patients. Training was significantly associated with greater competence and use of recommended practices. The underuse of assessment tools and expressed need for clearer guidelines suggest structural gaps in support and education.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Improving UI training and access to standardized tools could enhance physiotherapists' confidence and quality of care. Although conducted in France, these findings may inform international strategies to address similar gaps in geriatric continence care.</p>\u0000 </s","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/luts.70022","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144681423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lorenzo Campanella, Giovanni Grossi, Passarello Alessandra, Pietro Cignini, Fabio Manganelli, Pierluigi Palazzetti, M. A. Zullo, Andrea Morciano, Carlo Rappa, Francesco Deltetto, M. C. Schiavi
Objectives
The purpose of this research is to determine the effectiveness and safety of a vaginal mesh intended to resolve multicompartmental prolapse in individuals with substantial vaginal vault prolapse.
Methods
From 2015 to 2020, 67 patients with recurrent apical prolapse ≥ III stage (POP-Q grading) underwent transvaginal vault repair using the isoelastic mesh InGYNious. Operative time, blood transfusions, spontaneous voiding, perioperative issues, postoperative hospital stay, and postoperative complications (early within 30 days and late after 30 days) were also investigated. Following the first preoperative examination, clinical and QoL questionnaires were examined both before and after surgery at the long-term follow-up (> 60 months).
Results
The average surgery duration was 41 ± 21 min, with an estimated blood loss of 50 ± 21 mL. The total number of surgical complications was eight (11.9%). The study discovered significant reductions in the apical (from 1.88 ± 2.59 to −6.73 ± 1.77) and anterior (from 1.34 ± 1.67 to −2.25 ± 0.95) deficiencies, as well as improvements in PQOL (from 67.72 ± 19.25 to 33.74 ± 7.48), PISQ-12 (from 29 to 36), FSFI (from 20 to 29), and FSDS (from 21 to 8). Finally, we identified three cases of full recurrence and only two occurrences needed reoperation.
Conclusions
Transvaginal mesh repair is a safe and effective surgical technique that can treat multi-compartment prolapse, improve anatomical success, and reduce the risk of recurrence in certain patient populations, such as those with significant comorbidities, elderly patients, patients with recurrent POP, or patients with very challenging cases of POP.
{"title":"Is Vaginal Prosthetic Surgery Always to Be Avoided? Analysis of the Efficacy and Safety of Vaginal Mesh With 3 Levels-De Lancey Attachment in Women With Recurrent Vaginal Vault Prolapse","authors":"Lorenzo Campanella, Giovanni Grossi, Passarello Alessandra, Pietro Cignini, Fabio Manganelli, Pierluigi Palazzetti, M. A. Zullo, Andrea Morciano, Carlo Rappa, Francesco Deltetto, M. C. Schiavi","doi":"10.1111/luts.70021","DOIUrl":"https://doi.org/10.1111/luts.70021","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The purpose of this research is to determine the effectiveness and safety of a vaginal mesh intended to resolve multicompartmental prolapse in individuals with substantial vaginal vault prolapse.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>From 2015 to 2020, 67 patients with recurrent apical prolapse ≥ III stage (POP-Q grading) underwent transvaginal vault repair using the isoelastic mesh InGYNious. Operative time, blood transfusions, spontaneous voiding, perioperative issues, postoperative hospital stay, and postoperative complications (early within 30 days and late after 30 days) were also investigated. Following the first preoperative examination, clinical and QoL questionnaires were examined both before and after surgery at the long-term follow-up (> 60 months).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The average surgery duration was 41 ± 21 min, with an estimated blood loss of 50 ± 21 mL. The total number of surgical complications was eight (11.9%). The study discovered significant reductions in the apical (from 1.88 ± 2.59 to −6.73 ± 1.77) and anterior (from 1.34 ± 1.67 to −2.25 ± 0.95) deficiencies, as well as improvements in PQOL (from 67.72 ± 19.25 to 33.74 ± 7.48), PISQ-12 (from 29 to 36), FSFI (from 20 to 29), and FSDS (from 21 to 8). Finally, we identified three cases of full recurrence and only two occurrences needed reoperation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Transvaginal mesh repair is a safe and effective surgical technique that can treat multi-compartment prolapse, improve anatomical success, and reduce the risk of recurrence in certain patient populations, such as those with significant comorbidities, elderly patients, patients with recurrent POP, or patients with very challenging cases of POP.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144598213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bernadette Dellar, Ryan Stafford, Eric Chung, Gabriel Schaer, Margret Sherburn, Roxanna Turner, Handoo Rhee, Anna Page, Paul W. Hodges
Aims
This study aimed to assess the intra- and inter-tester repeatability of voiding sonography measures in asymptomatic women and to examine the effect of perineal transducer placement on uroflowmetry.
Methods
A prospective observational study of 32 asymptomatic women was conducted using ultrasound with simultaneous uroflowmetry. Participants completed four voids (two per day). The ultrasound transducer placed on the perineum assessed bladder neck and urethral displacement during micturition. On Day 1, a void with ultrasound and uroflow recorded by a sonographer was compared to a void recorded with uroflowmetry only to determine whether the transducer placement affected voiding. On Day 2, two sonographers evaluated the voids with ultrasound and uroflowmetry. Each sonographer measured their own images. One sonographer also made measures on the images recorded by the second sonographer. Uroflowmetry measures and void patterns were evaluated. The repeatability of ultrasound measures was analyzed using intraclass correlation coefficient (ICC 2,1) and Bland–Altman analysis, and t tests examined the transducer's impact on uroflowmetry.
Results
Some changes in flow rate and flow pattern (20% of participants) were observed with placement of the transducer. Most sonographic measures showed good to excellent inter- and intra-tester repeatability, and between measures made by the different testers on the same image. During void, bladder neck and urethral diameter were more repeatable if measures were made at the time of maximum flow estimated from the simultaneous uroflowmetry.
Conclusion
Voiding sonography is both feasible and repeatable. Perineal transducer placement affected micturition for some individuals. Voiding sonography combined with uroflowmetry shows promise for a noninvasive urogynecology functional assessment.
{"title":"A Repeatability Study of Measurement of Micturition With Voiding Sonography and Uroflowmetry of Asymptomatic Women","authors":"Bernadette Dellar, Ryan Stafford, Eric Chung, Gabriel Schaer, Margret Sherburn, Roxanna Turner, Handoo Rhee, Anna Page, Paul W. Hodges","doi":"10.1111/luts.70020","DOIUrl":"https://doi.org/10.1111/luts.70020","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to assess the intra- and inter-tester repeatability of voiding sonography measures in asymptomatic women and to examine the effect of perineal transducer placement on uroflowmetry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective observational study of 32 asymptomatic women was conducted using ultrasound with simultaneous uroflowmetry. Participants completed four voids (two per day). The ultrasound transducer placed on the perineum assessed bladder neck and urethral displacement during micturition. On Day 1, a void with ultrasound and uroflow recorded by a sonographer was compared to a void recorded with uroflowmetry only to determine whether the transducer placement affected voiding. On Day 2, two sonographers evaluated the voids with ultrasound and uroflowmetry. Each sonographer measured their own images. One sonographer also made measures on the images recorded by the second sonographer. Uroflowmetry measures and void patterns were evaluated. The repeatability of ultrasound measures was analyzed using intraclass correlation coefficient (ICC 2,1) and Bland–Altman analysis, and <i>t</i> tests examined the transducer's impact on uroflowmetry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Some changes in flow rate and flow pattern (20% of participants) were observed with placement of the transducer. Most sonographic measures showed good to excellent inter- and intra-tester repeatability, and between measures made by the different testers on the same image. During void, bladder neck and urethral diameter were more repeatable if measures were made at the time of maximum flow estimated from the simultaneous uroflowmetry.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Voiding sonography is both feasible and repeatable. Perineal transducer placement affected micturition for some individuals. Voiding sonography combined with uroflowmetry shows promise for a noninvasive urogynecology functional assessment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/luts.70020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144582184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We aimed to study the incidence of de novo and persistent stress urinary incontinence (SUI), urodynamic stress incontinence (USI) for single incision mesh (SIM) using Calistar-S and anterior mesh (A-mesh) using Surelift-A with sacrospinous fixation (SSF).
Methods
Patients with Stage III or IV POP who underwent Surelift-A + SSF (A-mesh + SSF) or Calistar-S (SIM) were evaluated at 1 year post-operative and compared. The primary outcome was the emergence of post-operative de novo and persistent SUI. Secondary outcomes included the rate of POP recurrence, quality of life, sexual function, and complications.
Results
One hundred and seven patients underwent SIM and 122 patients with A-mesh + SSF. 12/58 (20.7%) had de novo USI, 15/58 (25.9%) de novo SUI in SIM, while in the A-mesh + SSF group, de novo USI developed in 3/43 (7%) and de novo SUI in 4/43 (9.3%), significantly higher with p = 0.048 and p = 0.035 respectively. Rates of persistent USI and SUI were comparable between groups. Objective cure was comparable between the two groups (96.3% vs. 97.5%, p = 0.428), subjective cure 99/107 (92%) vs. 114/122 (93.8%) for SIM vs. A-mesh + SSF. Quality-of-life measures improved significantly in both groups, with greater perceived improvement in the A-mesh + SSF group. One case of bladder injury occurred in SIM and one mesh erosion was seen in both groups.
Conclusion
Risk of de novo SUI and de novo USI were three-fold higher in the SIM (Calistar-S), however risk of persistent USI and SUI was similar. Both SIM and A-mesh + SSF confer comparable high objective and subjective cure.
{"title":"Comparison of Urinary Incontinence Occurrence Among Patients With Advanced Pelvic Organ Prolapse After Single Incision Mesh (SIM) and Anterior Mesh (A-Mesh) With Sacrospinous Ligament Fixation (SSF) Surgery at 1 Year Follow-Up Study","authors":"Tsia-Shu Lo, Maherah Kamarudin, Huan-Ka Chiung, Eyal Rom, Louiza Erika Rellora, Wu-Chiao Hsieh","doi":"10.1111/luts.70017","DOIUrl":"https://doi.org/10.1111/luts.70017","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>We aimed to study the incidence of de novo and persistent stress urinary incontinence (SUI), urodynamic stress incontinence (USI) for single incision mesh (SIM) using Calistar-S and anterior mesh (A-mesh) using Surelift-A with sacrospinous fixation (SSF).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with Stage III or IV POP who underwent Surelift-A + SSF (A-mesh + SSF) or Calistar-S (SIM) were evaluated at 1 year post-operative and compared. The primary outcome was the emergence of post-operative de novo and persistent SUI. Secondary outcomes included the rate of POP recurrence, quality of life, sexual function, and complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One hundred and seven patients underwent SIM and 122 patients with A-mesh + SSF. 12/58 (20.7%) had de novo USI, 15/58 (25.9%) de novo SUI in SIM, while in the A-mesh + SSF group, de novo USI developed in 3/43 (7%) and de novo SUI in 4/43 (9.3%), significantly higher with <i>p</i> = 0.048 and <i>p</i> = 0.035 respectively. Rates of persistent USI and SUI were comparable between groups. Objective cure was comparable between the two groups (96.3% vs. 97.5%, <i>p</i> = 0.428), subjective cure 99/107 (92%) vs. 114/122 (93.8%) for SIM vs. A-mesh + SSF. Quality-of-life measures improved significantly in both groups, with greater perceived improvement in the A-mesh + SSF group. One case of bladder injury occurred in SIM and one mesh erosion was seen in both groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Risk of de novo SUI and de novo USI were three-fold higher in the SIM (Calistar-S), however risk of persistent USI and SUI was similar. Both SIM and A-mesh + SSF confer comparable high objective and subjective cure.</p>\u0000 </section>\u0000 </div>","PeriodicalId":18028,"journal":{"name":"LUTS: Lower Urinary Tract Symptoms","volume":"17 4","pages":""},"PeriodicalIF":1.5,"publicationDate":"2025-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144514852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号